Celemics, Inc. Overview
Celemics is a Seoul-based developer and manufacturer of hybridization-capture target enrichment reagents for next-generation sequencing (NGS), built on proprietary molecular-cloning (MSSIC™) and molecular-barcoding (BTSeq™) technology developed by its academic founders. It is one of a small number of companies globally — six, by the company's own IPO-era claim — capable of manufacturing target capture probe kits, and it describes itself as the only such manufacturer in Europe, Asia and the Middle East. Its revenue base remains very small (KRW 5.8 bn in FY2025) and has contracted since a FY2022 peak, with persistent operating losses since listing. In 2026 the company changed controlling shareholder, raised roughly KRW 31 bn through rights issues and convertible bonds, and pivoted toward a royalty-plus-kit model for US clinical oncology testing via a three-year, minimum-USD 7.225M agreement with San Diego CLIA lab Achieve Diagnostics. It is, in effect, a technology-rich but commercially sub-scale reagent maker attempting a clinical-market and M&A-led reset.
What the company does
Celemics designs, manufactures and sells reagents and services used in targeted NGS. Its core product is the target capture (target enrichment) kit: a pool of synthetic DNA/RNA probes that hybridize to selected regions of a genome so that only those regions are sequenced. Targeted sequencing is cheaper and deeper than whole-genome sequencing, and is the workhorse method for clinical cancer panels, hereditary-disease panels, exome sequencing and pathogen surveillance.
The company's technology stack, as described in its IPO materials and subsequent disclosures:
MSSIC™ (Massively Separated and Sequence-Identified Cloning): a high-throughput molecular cloning platform combining nano-optical techniques with NGS to isolate, propagate and sequence-verify very large numbers of DNA molecules at low cost. This is the foundational "DNA materials" technology from which probe pools are produced (Dealsite, 30 Jul 2020; Biospectator, 2020).
Probe design and rebalancing: after a pre-production pilot, Celemics rebalances individual probe concentrations to improve coverage uniformity, including in GC-rich and homologous regions that competitors are said to mask (GenomeWeb, US subsidiary launch; Medical-XPRT product page; Funakoshi distributor brochure).
BTSeq™ (Barcode-Tagged Sequencing): a unique-molecular-identifier (UMI) approach with error-removal algorithms, enabling accurate reads of long fragments (>1 kbp) and detection of rare variants below 1% variant allele frequency — relevant to liquid biopsy and minimal residual disease (Biospectator, 2020; Korea University TLO page).
Bioinformatics: Celemics Analysis Service (CAS), an end-to-end pipeline from FASTQ to annotated variants, and a "Sample-to-Report" offering run with Strand Life Sciences' StrandOmics (India) and the BlueBee cloud platform (Netherlands) (KU TLO page).
Business and revenue model
| Revenue stream | Description | Weight | Source |
|---|---|---|---|
| Target capture kits (product) | Custom and catalogue enrichment panels, whole exome, accessories (library prep, beads, enzymes) | ~85% of Q2 2026 revenue | Butler (DART-derived) |
| NGS services | Sequencing, bioinformatics, custom assay development, infectious-disease whole-genome sequencing for public agencies | ~15% of Q2 2026 revenue | Butler; KU TLO |
| Licensing / royalty (new from Q4 2026) | 20% royalty on Achieve Diagnostics' US clinical test net sales using five Celemics panels, plus minimum kit purchases | Not yet reported in revenue | MoneyToday, 4 Sep 2026; Hankyung, 1 Sep 2026 |
| Subscription | None identified | — | — |
Historically the model has been a classic research-use-only (RUO) reagent business: one-off and repeat kit sales to hospitals, reference laboratories, pharmaceutical companies, seed/breeding companies and research institutes (Asia Economy, Aug 2024). The 2026 Achieve agreement introduces the first disclosed volume-linked royalty stream tied to reimbursed US clinical testing.
Value-chain position
Celemics sits in the upstream consumables layer of the NGS value chain: it supplies the enrichment chemistry that sits between sample preparation (DNA extraction, library preparation) and sequencing instruments (dominated by Illumina, with MGI, Thermo Fisher and PacBio as alternatives). Its kits are stated to be compatible with Illumina, Thermo Fisher, Pacific Biosciences and MGI instruments (Medical-XPRT product page), which positions it as an instrument-agnostic second source. Downstream, it partially integrates into services (sequencing and bioinformatics) and, from 2026, into clinical testing economics via royalties.
Customer types and end-markets
Customers named or described in public sources: hospitals, contract testing labs, pharmaceutical companies, seed companies, research institutes (Asia Economy, Aug 2024); the Korea Disease Control and Prevention Agency (KDCA) for 2025–2026 infectious-disease surveillance; National Cancer Center Korea (collaboration); distributors and partners in China (Sangon Biotech; earlier Tsingke via distributor Forcula), India (Imperial Life Science), Japan (Funakoshi) and the US (Achieve Diagnostics; MedCare Partners Health Plan of Texas MOU).
End-markets: oncology (hereditary and somatic), rare/inherited disease (clinical exome), pharmacogenomics, infectious disease and pathogen surveillance, liquid biopsy, immune-repertoire/antibody discovery, agrigenomics/breeding, microbiome and synthetic biology.
Company's own description vs. independent characterization
Company description (paraphrased from 2026 press materials and IR): an NGS specialist operating a platform business built on MSSIC since 2010, applied across medicine, drug development, microbiome, synthetic biology and breeding, and the self-producing target capture kit maker in Europe, Asia and the Middle East; in 2026 it framed its strategy as a "two-track" of strengthening the NGS core while investing in new businesses (VentureSquare, 8 Jun 2026).
Independent characterization: Celemics is a technically credible but commercially sub-scale reagent company. Six years after listing it has never generated an operating profit, its revenue (KRW 5.8 bn in FY2025) is lower than in FY2021, and it missed its IPO-era revenue projections by roughly 90% (Dealsite, 24 Oct 2025). Its only profitable year (FY2024) was driven entirely by a fair-value gain on a minority stake in IMBdx. The 2026 change of control, aggressive equity/CB issuance, an earmarked ~KRW 11.5 bn for acquiring "other companies' securities", and an above-market third-party issue to an entity named C&P point to a balance-sheet and strategic reset whose end-state is not yet disclosed. The Achieve contract is the first commercial evidence that the core technology can be monetized at scale in the US, but it is a minimum commitment from a single counterparty that had no prior NGS testing capability.
Strategy
Stated strategy (themes, paraphrased)
From the company's June 2026 statements: Celemics describes a "two-track" strategy — (1) upgrade and strengthen the core NGS business, and (2) secure new growth engines through strategic investments and new-business entry with synergy to NGS, funded by approximately KRW 11.5 bn of the 2026 proceeds earmarked for acquiring other companies' securities. The company said specific investment plans would be disclosed sequentially (VentureSquare, 8 Jun 2026). From September 2026: the company aims to become a US clinical diagnostics player, initially through Achieve's CLIA lab, and then expand into liquid biopsy, precision oncology and companion diagnostics (Hankyung, 1 Sep 2026). From October 2025: re-pointing overseas expansion from China to the US and India via subsidiaries and branches (Dealsite, 24 Oct 2025).
Strategic initiatives — last 24 months
| Initiative | Date | Description | Status | Source |
|---|---|---|---|---|
| Achieve Diagnostics license + kit supply | 31 Aug 2026 – 30 Aug 2029 | Exclusive US license for five cancer panels; 20% royalty on net test sales; min. USD 4.75M kit purchases + min. USD 2.475M royalties = USD 7.225M | Effective | Hankyung; MoneyToday |
| MCPTX MOU | 20 Jul 2026 | Evaluate/implement NGS cancer tests (hereditary, somatic, colorectal, breast, lung) with a Texas Medicare-focused health plan | Non-binding MOU | CB Insights / EIN Presswire |
| Two-track recapitalization | Feb–Jun 2026 | ~KRW 31 bn raised via rights issues and CBs | Completed | VentureSquare |
| C&P strategic issue | Jul 2026 | KRW 10 bn for acquisition of other companies' securities | Approved; completion unconfirmed | Bullstory; Littlebit |
| CancerMaster commercialization | 2,026 | 524-gene CGP panel, Illumina-compatible, priced at 1/3–1/4 of competitors | Marketing phase | Sat Economy |
| KDCA infectious-disease surveillance | 2025–2026 | National WGS surveillance support | Active | KU TLO |
| India expansion | 2023– | Subsidiary + Imperial Life Science distribution | Active | KU TLO |
| US RUO reagent seeding | 2,025 | Free CeleMag bead samples for validation partners; AMO-MAG cfDNA kit partnership | Active | |
| National R&D programs | 2,024 | Government projects in breeding, biobank and cancer gene panels; 12 national R&D projects in total | Ongoing | TheVC |
Sustainability / ESG commitments: none disclosed. Cost programs with targets: none disclosed. Medium-term financial targets / guidance: no current guidance published. The only quantified targets on record are the IPO-era projections (2020), which were missed by ~90%.
Products & Services
Pricing for all products is quote-based and not publicly disclosed, except for the company's comparative claim on CancerMaster.
Target enrichment panels — oncology
| Product | Description / capability | Target customer | Year | Source |
|---|---|---|---|---|
| CancerMaster | Comprehensive genomic profiling panel analysing 524 cancer-related genes in a single test; runs on installed Illumina sequencers; company claims test cost ~1/3 to 1/4 of competing products; Yonsei medical researchers reported high-accuracy detection of actionable variants in solid tumours and some variants missed by the comparator | Hospital molecular pathology labs, reference labs, global precision oncology | Publicised 2026 | Sat Economy, 2026 |
| OncoRisk Panel | Hereditary cancer risk genes | Clinical labs; licensed to Achieve Diagnostics (US) | In portfolio by 2023; US license 2026 | BiopharmIQ; Hankyung, Sep 2026 |
| CancerScreen / Cancer Screen 50 Panel | Somatic solid-tumour panel (~50 genes) | Clinical labs; licensed to Achieve | 2026 US license | Hankyung; MoneyToday |
| ctDNA Breast Cancer Panel | Circulating tumour DNA panel for breast cancer (liquid biopsy) | Clinical labs; licensed to Achieve | 2,026 | Hankyung |
| ctDNA Colorectal Cancer Panel | ctDNA panel for colorectal cancer | Clinical labs; licensed to Achieve | 2,026 | Hankyung |
| ctDNA Lung Cancer Panel | ctDNA panel for lung cancer | Clinical labs; licensed to Achieve | 2,026 | Hankyung |
| BRCA1/2 Panel | Hereditary breast/ovarian cancer genes | Clinical labs | Shown 2020 | Biospectator, 2020 |
| Pan-Cancer Panel | Multi-tumour somatic panel | Clinical labs | Shown 2020 | Biospectator, 2020 |
| Sarcoma NGS panel | Sarcoma-focused panel | Clinical/research | Listed 2026 | KU TLO keywords |
| MRD kit | Minimal residual disease detection (BTSeq-based) | Oncology research/clinical | Program disclosed 2020 | Daishin, Dec 2020 |
Target enrichment panels — germline, exome and pharmacogenomics
| Product | Description / capability | Target customer | Source |
|---|---|---|---|
| Celemics Whole Exome | 37 Mb panel covering target regions of major commercial WES panels with >98% coverage; optional mitochondrial/intronic spike-ins; supported by CAS | Research and clinical genomics labs | Medical-XPRT |
| Clinical Exome Sequencing (CES) Panel | Disease-associated exome for rare/hereditary disease diagnosis; flagship product in India | Hospital genetics labs; India via Imperial Life Science | KU TLO; Biospectator 2020 |
| PharmacoScreen | Pharmacogenomic panel | Clinical labs, pharma | BiopharmIQ; Biospectator 2020 |
| Custom Target Enrichment Panels | Customer-specified genes/hotspots; detects all four variant classes; detailed QC on standard DNA samples provided at development | Labs, pharma, diagnostics developers | Medical-XPRT; Biospectator 2020 |
Infectious disease and agrigenomics
| Product / service | Description | Customer | Source |
|---|---|---|---|
| Comprehensive Respiratory Virus panel | Hybrid-capture respiratory pathogen panel | Public health, hospital labs | BiopharmIQ |
| Influenza / COVID-19 WGS service | Whole-genome sequencing for variant surveillance; H5N1 work promoted | KDCA (2025–2026 contract) | KU TLO; LinkedIn |
| Amplicon- and hybrid-based pathogen enrichment | Microbiology end-to-end NGS offering promoted at ASM Microbe 2025 | Microbiology labs | |
| Agrigenomics panels | Breeding/seed-company genotyping | Seed companies, breeding programs | BiopharmIQ; Asia Economy |
Platform technologies and research solutions
| Product | Description | Source |
|---|---|---|
| MSSIC™ | High-throughput, sequence-verified molecular cloning platform underpinning probe manufacture | Dealsite 2020; Biospectator |
| BTSeq™ | UMI-based barcode-tagged sequencing; long-read accuracy >1 kbp; VAF <1% sensitivity; technology supply to China in 2021 | Biospectator; Dailypharm; KU TLO |
| True Repertoire™ | Immune repertoire / antibody discovery acceleration solution | Biospectator, 2020 |
Modular accessories (reagents)
| Product | Function | Source |
|---|---|---|
| Library Preparation Kit | NGS library construction | Simply Wall St; Dealsite image |
| Double-stranded cDNA synthesis kit | RNA-to-cDNA for capture | Simply Wall St |
| Hybridization Enhancer | Capture efficiency | Simply Wall St |
| Clean-up beads; Streptavidin beads | Purification; capture pull-down | Simply Wall St |
| CeleMag (Celemag) beads; CeleNM beads | Magnetic beads; free samples offered to US validation partners in 2025 | Simply Wall St; LinkedIn |
| Polymerase | Amplification enzyme | Simply Wall St |
| Kit formats: Target Enrichment Kit / Standard Kit / All-in-one Kit | Configurations sold via Japanese distributor | Funakoshi brochure |
| AMO-MAG Cell-Free DNA Isolation Kit (partner product) | cfDNA and blood gDNA extraction, introduced with AMO Lifescience |
Services
| Service | Description | Source |
|---|---|---|
| Celemics Analysis Service (CAS) | FASTQ-to-report bioinformatics: variant type, VAF, pathogenicity | Medical-XPRT |
| Sample-to-Report | One-stop sample receipt through clinical report, with StrandOmics (Strand Life Sciences) and BlueBee cloud | KU TLO |
| Sequencing services | Contract sequencing (excluded from the original US subsidiary's scope) | GenomeWeb; Simply Wall St |
| Custom NGS assay development / biopharma services | Panel design and validation for pharma and diagnostics developers | Simply Wall St |
Financial Narrative
Basis: K-IFRS consolidated, fiscal years ending 31 December. FY2021–FY2025 headline figures from Dealsite (24 Oct 2025, citing filings) and Butler (DART-derived); FY2025 detail and trailing-twelve-month (TTM) figures from ValueLine (DART-derived, 26.2Q update). Rounded to KRW 0.1 bn; margin calculations by analyst from rounded figures.
Income statement — 5-year
Reference years: FY2019 revenue KRW 5.14 bn (+34.9% YoY), operating loss KRW 5.0 bn; FY2020 revenue KRW 5.3 bn (+2.4%), operating loss KRW 4.9 bn (Daishin IPO reports, Dec 2020 / Jun 2021). FY2025 YoY growth of -14.2% is as reported by Butler on unrounded figures.
Revenue CAGR FY2021–FY2025: approximately -8.0% per year (analyst calculation, KRW 8.1 bn → 5.8 bn).
FY2025 and latest TTM detail
Note: the 2025 consolidated revenue is given as approximately KRW 5.77 bn in the company's Achieve-related statement (Hankyung, 1 Sep 2026), consistent with ValueLine's KRW 5.76 bn.
Derived H1 2026 (analyst calculation; not a reported figure): using TTM to June 2026 minus FY2025 plus H1 2025 (H1 2025: revenue KRW 2.8 bn, operating loss KRW 1.8 bn, net loss KRW 5.1 bn per Dealsite), H1 2026 implies revenue of roughly KRW 2.3 bn (≈ -19% YoY), operating loss of roughly KRW 2.4 bn and net loss of roughly KRW 11.2 bn. The net loss is dominated by fair-value losses on financial assets (IMBdx stake and/or CB-related derivatives). These derived figures should be checked against the half-year report filed 14 Aug 2026.
Balance sheet
Simply Wall St characterized the balance sheet as low-risk (no material debt) as of its late-2025 data, before the 2026 CB issuance.
Commentary — trends, inflections and drivers
Revenue. Revenue rose sharply in FY2021 (+53%) on the back of COVID-era sequencing demand and the July 2021 Tsingke/China contract, peaked at KRW 8.7 bn in FY2022, then fell 24% in FY2023 as pandemic-related work faded and the China channel collapsed. FY2024 was flat; FY2025 fell 14%, and the TTM figure to June 2026 (KRW 5.2 bn) shows continued contraction. The company attributes the stagnation to the pandemic freezing its overseas brand-building immediately after IPO and to the cancellation of a >KRW 10 bn China order, and says it has re-pointed its strategy toward the US and India (Dealsite, 24 Oct 2025). The domestic NGS market is small, so overseas growth is essential by the company's own account.
IPO-target gap. At IPO the company projected KRW 15 bn revenue and operating breakeven within two years, and revenue of KRW 27.9 bn (2022), KRW 46.9 bn (2023) and KRW 69.9 bn (2024), with operating profit reaching KRW 33.4 bn by 2024. Actual FY2024 revenue was under 10% of target; Dealsite computed a 90.4% shortfall for 2024. This is the single most important credibility fact in the dossier.
Gross margin. At roughly 43–50% gross margin, Celemics earns far below the 60%+ typical of scaled reagent franchises, reflecting sub-scale manufacturing overhead (labour of ~KRW 1.5 bn and depreciation in cost of sales against only ~KRW 5–6 bn revenue). Gross margin compressed from ~50% in FY2025 to ~43% TTM as revenue shrank against a fixed cost base.
Operating costs. SG&A including R&D has been stable at roughly KRW 6.0–6.2 bn, with salaries ~KRW 2.2 bn, fees ~KRW 1.0–1.5 bn and R&D ~KRW 1.0–1.1 bn (ValueLine). The FY2024 operating-loss improvement to KRW 1.9 bn appears to have been a one-year cost-control effect that reversed in FY2025 (KRW 3.3 bn loss).
Below-the-line volatility. Net income is dominated by fair-value movements on the IMBdx stake: a gain of roughly KRW 13 bn in FY2024 when IMBdx listed, then losses of KRW 3.5 bn in H1 2025 alone as IMBdx shares fell from KRW 36,000 at listing to ~KRW 10,400 by October 2025 (Dealsite, 27 Oct 2025). TTM financial valuation losses of KRW 6.3 bn and new interest expense of KRW 0.44 bn (CB accretion) drove the TTM net loss to KRW 10.2 bn. The company has said it has no plan to sell the IMBdx stake.
Inflection candidates. (1) Achieve Diagnostics minimum commitments of ~USD 2.4M per year equate to ~57% of FY2025 revenue annually, if performed. (2) KDCA surveillance contract through 2026. (3) India subsidiary scaling. Against these: shrinking base business and rising financial costs.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Lines
| Business line (as reported) | Contents | Share of revenue | Period | Source |
|---|---|---|---|---|
Target Capture kits | Custom and catalogue hybrid-capture panels, whole exome, accessories | 85% | Q2 2026 | Butler (DART-derived) |
NGS services | Sequencing, bioinformatics (CAS), custom assay development, infectious-disease WGS for KDCA | 15% | Q2 2026 | Butler (DART-derived) |
Revenue by Segment
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total revenue (KRW Bn) | 8.1 | 8.7 | 6.6 | 6.7 | 5.8 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansGroup Entities
| Entity | Jurisdiction | Function | Status | Source |
|---|---|---|---|---|
Celemics, Inc. | Korea | Parent; R&D, manufacturing, sales | Listed | DART |
Celemics America / Celemics USA | California, USA (Irvine at launch; Santa Ana in later directory listings) | Kit sales and business development | Active (consolidated) | GenomeWeb; BiopharmIQ; LinkedIn |
Celemics India subsidiary | India (city not disclosed) | Sales; CES panel distribution with Imperial Life Science | Established 2023 | KU TLO page |
IMBdx, Inc. | Korea (KOSDAQ-listed) | Financial investment, ~9.8% stake at 30 Jun 2025 (FVTPL) | Not consolidated | Dealsite, 27 Oct 2025 |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 8.1 | 8.7 | 6.6 | 6.7 | 5.8 |
Revenue growth YoY (%) | 52.8 | 7.4 | -24.1 | 1.5 | -14.2 |
Operating income (KRW Bn) | -6.0 | -5.7 | -5.8 | -1.9 | -3.3 |
Net income (KRW Bn) | -5.2 | -4.8 | -3.9 | 12.3 | -4.0 |
Operating margin (%) | -74.1 | -65.5 | -87.9 | -28.4 | -56.9 |
Net margin (%) | -64.2 | -55.2 | -59.1 | 183.6 | -69.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%) and Per-Share Data
| Line item | FY2025 (KRW Bn) | TTM to 30 Jun 2026 (KRW Bn) | Source |
|---|---|---|---|
Revenue | 5.76 | 5.22 | ValueLine |
Cost of revenue | 2.90 | 2.98 | ValueLine |
Gross profit | 2.86 | 2.23 | ValueLine |
Gross margin | 49.7% | 42.7% | Analyst calc. |
SG&A (incl. R&D) | 6.19 | 6.11 | ValueLine |
of which R&D expense | 1.03 | 1.10 | ValueLine |
Operating income | -3.32 | -3.88 | ValueLine |
EBITDA | -3.60 | -9.26 (aggregator figure; appears to include non-operating items — treat with caution) | ValueLine |
Net financial result | -0.71 | -6.45 | ValueLine |
of which FVTPL valuation losses | -1.04 | -6.27 | ValueLine |
Interest expense | 0.01 | 0.44 | ValueLine |
Pre-tax income | -4.03 | -10.16 | ValueLine |
Income tax | 0.00 | 0.00 | ValueLine |
Net income | -4.03 | -10.16 | ValueLine |
EPS, basic (KRW) | -494 | -1,140 | ValueLine |
EPS, diluted | Not separately disclosed (anti-dilutive) | — | — |
Dividends per share (KRW) | 0 | 0 | StockHub (yield 0.00%) |
Financial Analysis
| Item | Value | Date | Source / method |
|---|---|---|---|
Total equity | ≈ KRW 30.4 bn | 30 Jun 2026 | Derived: market cap KRW 110.0 bn ÷ P/B 3.62 (ValueLine, 15 Oct 2026); consistent with ROE -33.45% on TTM loss |
IMBdx stake (FVTPL) carrying value | KRW 14.6 bn → KRW 11.2 bn | 31 Dec 2024 → 30 Jun 2025 | Dealsite, 27 Oct 2025 |
Convertible bonds outstanding | ≈ KRW 15 bn (derived: KRW 31 bn total raise less ~KRW 4.3 bn and ~KRW 11.6 bn equity) | Mid-2026 | Analyst derivation from VentureSquare / Edaily; not confirmed |
Net debt | Not computable from sources reviewed; likely net cash post-2026 raises | — | — |
Goodwill and intangibles | Not publicly disclosed (intangible amortization only ~KRW 0.01–0.03 bn p.a. per ValueLine, implying minimal intangibles) | — | ValueLine |
Financial Analysis — Operating cash flow FY2021–FY2025
| Item | Status |
|---|---|
Operating cash flow FY2021–FY2025 | Not publicly disclosed in sources reviewed. Given persistent operating losses of KRW 1.9–6.0 bn and depreciation of only ~KRW 0.6 bn p.a., operating cash flow has almost certainly been negative every year. |
Capex | Not publicly disclosed in sources reviewed. Depreciation of ~KRW 0.4 bn (cost of sales) + ~KRW 0.2 bn (SG&A) p.a. suggests a light asset base. |
Free cash flow | Not publicly disclosed; inferred negative |
Dividends paid | Zero (no dividend history) |
Share buybacks (company) | None identified. Insider purchases in 2026 were personal, not company buybacks |
Financing inflows | FY2026 YTD: ≈ KRW 31 bn from rights issues and CBs (VentureSquare); KRW 10 bn C&P issue approved but completion not confirmed |
Financial Analysis (Annual)
| Ratio | FY2025 / latest | Source / method |
|---|---|---|
ROE | -33.45% (TTM) | ValueLine |
ROA | Not computable (total assets not disclosed) | — |
ROIC | Not computable | — |
Debt / equity | ≈ 0.5x (≈ KRW 15 bn CB ÷ ≈ KRW 30.4 bn equity; derived, unconfirmed) | Analyst |
Net debt / EBITDA | Not meaningful (negative EBITDA) | — |
Interest coverage | Not meaningful (negative EBIT) | — |
Asset turnover | Not computable | — |
Gross margin | 49.7% (FY2025); 42.7% (TTM Jun-2026) | ValueLine / analyst |
R&D / revenue | 17.9% (FY2025); 21.1% (TTM) | ValueLine / analyst |
Price / book | 3.62x | ValueLine, 15 Oct 2026 |
Price / sales (TTM) | ≈ 21x | Analyst: KRW 110.0 bn ÷ KRW 5.22 bn |
Region Overview
| Region | Channel / evidence | Direction | Source |
|---|---|---|---|
Korea | Direct sales to hospitals, labs, research institutes, seed companies; KDCA 2025–2026 contract; National Cancer Center collaboration | Core market; described by company as small and limited | Dealsite; KU TLO |
China | 2021 KRW 4.5 bn BTSeq contract (Tsingke via Forcula); Sangon Biotech cited as kit/technology partner; >KRW 10 bn order cancelled | Declined after 2021; company has de-emphasized China | Dailypharm; KU TLO; Dealsite |
India | Subsidiary established 2023; ~KRW 0.5 bn first-year sales; CES panel via Imperial Life Science; Strand Life Sciences bioinformatics partner | Growing (company names India a priority) | KU TLO; Dealsite |
United States | Subsidiary since c. 2013 (Irvine; later Santa Ana); RUO kit sales; Achieve Diagnostics license from 31 Aug 2026; MCPTX MOU July 2026 | Expected to become largest growth driver from Q4 2026 if contract performs | GenomeWeb; Hankyung; CB Insights |
Japan | Distributor Funakoshi | Not quantified | Funakoshi brochure |
Middle East / Europe | MEDLAB Middle East exhibitor since 2017; BlueBee (Netherlands) partner; IPO-era claim of capture-kit customers in Europe/Middle East | Not quantified | Biospectator; KU TLO |
Share Price and Market Valuation
| Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Quarter-end share price (KRW) | 3,000 | 2,995 | 2,715 | 12,620 | 11,970 |
Quarter-end market cap (KRW Bn) | 24.5 | 24.5 | 22.2 | 103.0 | 117.3 |
Share Price & Returns
| Reference point | Price (KRW) | Source |
|---|---|---|
IPO price (Aug 2020) | 20,000 | Biospectator |
31 Aug 2020 close | 26,200 | Dealsite |
24 Dec 2020 | 25,500 | Daishin |
28 Jun 2021 | 18,150 | Daishin |
12 Aug 2024 (intraday, limit-up) | 5,200 | Asia Economy |
31 Dec 2025 | 2,715 | ValueLine |
52-week low / high | 2,535 / 19,840 | Google Finance |
15 Oct 2026 close | 9,640 | ValueLine |
Valuation Multiples
| Multiple | Celemics | Peer comparison |
|---|---|---|
Market cap | ≈ KRW 110.0 bn | — |
P/E | Not meaningful (TTM EPS KRW -1,140; aggregator shows -10.8x) | — |
EV/EBITDA | Not meaningful (negative EBITDA) | — |
EV/Sales | Not computed (cash and debt not disclosed); P/S ≈ 21x TTM | — |
P/B | 3.62x | — |
StockHub peer screen | Valuation in top 16% of Korean medical-device peers (rich) | StockHub, Oct 2026 |
Capital Markets
| Item | Status | Source |
|---|---|---|
Current analyst consensus | None — zero reports in sample | StockHub |
Historical coverage | Shinhan Investment initiated Buy, TP KRW 40,000 (Aug 2020); Daishin issued mandatory IPO-manager reports, not rated (2020–2021) | MTN; Daishin |
Dividend history / policy | No dividends paid; yield 0.00% | StockHub |
Company buyback authorizations | None identified | — |
Insider purchases | Co-CEO, executives and Director Lee Sang-seok bought shares in 2026 | TheVC |
Credit ratings (Moody's / S&P / Fitch / Korean agencies) | None — unrated | — |
Debt maturity profile | CB terms (coupon, maturity, put/call, conversion price) not publicly disclosed in sources reviewed. Korean private CBs commonly carry 3–5 year maturities with investor put options after 1–2 years, which would create potential cash calls from 2027–2028; this is a structural observation, not a confirmed term | — |
Share Count (millions)
| Metric | Pre-Feb 2026 | Post-Feb issue (Jun 2026) | Oct 2026 | Potential post-C&P |
|---|---|---|---|---|
Shares outstanding (millions) | 8.16 | 9.80 | 11.18 | 12.10 |
Analyst Conclusions
Management guidance and consensus
No formal financial guidance has been published; no consensus estimates exist. The only quantified forward commitment is the Achieve minimum: USD 4.75M of kit purchases plus USD 2.475M of royalties (20% of a USD 12.375M minimum net test-sales commitment) over 31 Aug 2026 – 30 Aug 2029, with automatic one-year renewals absent notice 90 days before expiry (MoneyToday; Hankyung). Spread evenly, this implies roughly USD 2.4M (≈ KRW 3.3 bn) per year — about 57% of FY2025 revenue — but contract-year phasing is not disclosed, and minimums may be back-weighted.
Bull case
-
Achieve converts Celemics into a recurring-revenue story. Minimums alone would lift annual revenue by roughly half; royalties scale with volume, and only ~172 tests per month at USD 2,000 net are needed to hit the minimum net-sales commitment (MoneyToday). Upside if Achieve's affiliated hospital-contracting organization (hundreds of staff) drives volume.
-
Low-cost CGP has a real market. A 524-gene panel at 1/3–1/4 of competitor pricing on installed Illumina instruments, with peer-reviewed Yonsei data, is a credible wedge for reference labs and emerging markets (India, Middle East).
-
Balance sheet de-risked. ~KRW 31 bn raised in 2026 against an operating burn of ~KRW 3–4 bn per year provides multi-year runway and capacity for accretive bolt-ons; insiders have been buying.
Bear case
-
Track record argues for heavy discounting. Revenue has fallen for most of the post-IPO period, sits ~90% below IPO projections, and the core business is still shrinking (TTM KRW 5.2 bn).
-
The 2026 financing pattern resembles a control-transfer/M&A vehicle more than an operating turnaround. Earmarking ~KRW 11.5 bn (plus a KRW 10 bn C&P issue) for undisclosed "other companies' securities", after-hours change-of-control disclosure, and an above-market C&P subscription raise the risk that capital is deployed outside the NGS core.
-
Valuation already discounts success. At ~21x TTM sales and 3.6x book after a ~255% YTD rally, the market capitalization (~KRW 110 bn) is ~11x the entire three-year Achieve minimum; with no coverage and low liquidity, downside on any Achieve under-performance or failed C&P funding could be severe.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Why it matters | Expected timing |
|---|---|---|
| First Achieve kit orders and royalty recognition | Proof of contract performance | Q4 2026 – Q1 2027 results |
| Q3 2026 quarterly report | Revenue trajectory; CB/derivative accounting; cash position | Mid-Nov 2026 |
| Completion or cancellation of KRW 10 bn C&P issue | Funding certainty; signal on M&A plans | Pending |
| Disclosure of "other companies' securities" acquisitions | Determines whether capital stays in NGS or diversifies | Company said "sequentially" |
| MCPTX MOU conversion to a definitive agreement | Payer-side volume | 2026–2027 |
| KDCA contract renewal beyond 2026 | Domestic base revenue | Late 2026 / early 2027 |
| FY2026 business report: pre-tax loss vs. equity, revenue vs. listing thresholds | KOSDAQ listing-maintenance compliance | Mar 2027 |
| IMBdx share price | Drives FVTPL gains/losses | Continuous |
| CB conversion / put dates | Dilution or cash outflow | Terms not disclosed |
| India subsidiary growth; CancerMaster adoption | Diversification of growth | 2026–2027 |
Analyst verdict
Celemics is a genuine technology company trapped inside a sub-scale business. Its founders built a rare capability — independent manufacture of hybrid-capture probe pools with good uniformity and molecular-barcoding chemistry — that very few companies outside the US and China possess. Yet six years after a heavily oversubscribed IPO, the company has never earned an operating profit, its revenue is lower than in 2021, and it delivered roughly a tenth of what it promised investors at listing. Its single profitable year was an accounting gain on someone else's IPO.
2026 changed the shape of the story rather than its substance. The Achieve Diagnostics agreement is the most important commercial event in the company's history: it is structured intelligently, with minimum commitments, a 20% royalty on reimbursed US tests and an exclusivity-termination remedy, and its minimums alone are material relative to Celemics' revenue. If it performs, Celemics moves from selling research reagents to participating in clinical test economics — the right strategic direction for an independent probe maker. CancerMaster's low-cost positioning gives the platform a second credible wedge.
Against this, the governance and capital-allocation signals are mixed to negative. Control passed to a new shareholder whose background is not publicly documented, through a low-priced placement disclosed after hours on a limit-up day. A substantial share of the ~KRW 31 bn raised is earmarked for acquiring undisclosed companies, and a further KRW 10 bn issue sits at roughly twice the market price with uncertain completion. The equity has already re-rated ~3.5x year-to-date to a valuation that implies substantial over-delivery on Achieve.
Verdict: technologically interesting, commercially unproven, and governance-sensitive. The investment case rests on verifiable execution — Achieve royalties appearing in Q4 2026/Q1 2027 filings and capital being deployed into NGS-adjacent assets. Until both are evidenced, Celemics should be treated as a high-risk, event-driven special situation rather than a fundamental growth holding.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / role history | Background | Source |
|---|---|---|---|---|
Park Jong-gap (박종갑) | Co-CEO (Representative Director); largest shareholder | Acquired control Feb 2026; listed as representative director on Feb 2026 filing | Prior roles and education not publicly disclosed in sources reviewed | DART filing; Edaily; KU TLO |
Kim Hyo-ki (김효기) | Co-CEO (Representative Director); co-founder | Co-founder 2010; co-CEO pre-IPO to present; largest shareholder until Feb 2026 | Founder; promotes company at international conferences | Dealsite 2020; Edaily 2026 |
Lee Yong-hoon (이용훈) | Former CEO / former co-CEO | CEO at 2020 IPO; sold shares in Feb 2026 change of control; participated in mid-2026 rights issue as "former CEO" | — | Dealsite 2020; Edaily 2026; VentureSquare 2026 |
Lee Sang-seok (이상석) | Director; Head of Management Support (filing officer) | In role 2026; bought shares on market 2026 | — | DART filing; TheVC |
Kwon Sung-hoon (권성훈) | Co-founder | — | Academic | Dealsite, 2020 |
Bang Doo-hee (방두희) | Co-founder | — | Academic | Dealsite, 2020 |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change | Context | Source |
|---|---|---|---|
3 Feb 2026 (filing) | Park Jong-gap becomes largest shareholder and co-CEO; Lee Yong-hoon exits co-CEO role | Lee Yong-hoon and Kim Hyo-ki sell ~430,000 shares (5.27%) at KRW 6,000/share to Park; Park subscribes 760,746 new shares | Edaily, 11 Feb 2026 |
13 Jul 2026 (filing) | Outside director appointment/resignation | Details not disclosed in sources reviewed | Butler |
Sep–Oct 2026 | Co-CEO and executives purchase shares on market | Stated purpose: responsible management | TheVC |
Major Shareholders
| Holder | Stake | Basis | Source |
|---|---|---|---|
Park Jong-gap | ≈ 1.19M shares (≈ 10.7%) — analyst estimate: 430,000 acquired + 760,746 new shares ÷ 11.18M; excludes any subsequent trades | Derived | Edaily; Google Finance |
Kim Hyo-ki | Residual stake after Feb 2026 sale not disclosed | — | — |
C&P (씨앤피) | 915,000 shares (≈ 7.6% post-issue) if KRW 10 bn issue completes; completion not confirmed | Conditional | Littlebit; Bullstory |
Investment partnership including a US medical-school professor ("Professor Kim", biomedical engineering; publication tag references Johns Hopkins) | Participated in mid-2026 rights issue; stake not disclosed | — | VentureSquare, Jun 2026 |
IMBdx-related, Partners Investment, WONIK Investment Partners | Historical investors; current holdings not disclosed | — | Dealsite 2020; CB Insights |
Competitive Landscape
Key Competitors
| Competitor | Relevant franchise | Segment overlap | Positioning vs. Celemics |
|---|---|---|---|
Agilent Technologies (USA) | SureSelect hybrid-capture panels and exomes | Target enrichment, exome, custom panels | Global incumbent; far larger scale and installed clinical base |
Twist Bioscience (USA) | Silicon-synthesized hybrid-capture probes, exome, custom panels | Target enrichment, custom panels | Fastest-growing pure-play probe supplier; synthesis-cost leader |
Integrated DNA Technologies (Danaher) | xGen hybridization capture | Target enrichment | Broad oligo franchise; strong US channel |
Roche (Switzerland) | KAPA HyperCap / HyperChoice, KAPA library prep | Target enrichment, library prep | Integrated workflow vendor |
Illumina (USA) | TruSight Oncology 500, enrichment kits; sequencers | CGP panels (CancerMaster comparator), enrichment | Platform owner; CancerMaster priced at a stated 1/3–1/4 of competing products |
Thermo Fisher Scientific (USA) | Ion AmpliSeq / Oncomine (amplicon) | Oncology panels (different chemistry) | Amplicon alternative on Ion Torrent |
QIAGEN (Netherlands) | QIAseq targeted panels (UMI-based) | UMI panels (BTSeq overlap) | UMI chemistry competitor |
MGI Tech (China) | MGIEasy exome/capture kits; sequencers | Exome, China market | Low-cost instrument ecosystem |
Pillar Biosciences (USA) | SLIMamp oncology panels | Oncology panels | Clinical kit focus |
Chinese probe makers (e.g., iGeneTech, Nanodigmbio) | Hybrid-capture probes | Target enrichment in China | Price competition in China |
Dxome (Korea) | DxSeq NGS panels | Korean clinical panels | Domestic panel competitor |
NGeneBio (Korea) | BRCAaccuTest, oncology panels | Korean clinical panels | Domestic competitor |
GC Genome / Macrogen (Korea) | Clinical and research sequencing services | NGS services | Service-side competitors (and occasional partners) |
IMBdx (Korea) | AlphaLiquid liquid biopsy | Liquid biopsy | Adjacent; Celemics is a ~9.8% shareholder |
Peer Comparison FY2024
| Company | Fiscal year | Revenue | Revenue growth | Notes |
|---|---|---|---|---|
Celemics | FY2025 | KRW 5.8 bn (≈ USD 4.2M) | -14.2% | Operating margin -57%; R&D 18% of revenue |
Illumina | FY2024 | USD 4.37 bn | ≈ -3% | — |
Agilent Technologies | FY2024 (Oct) | USD 6.51 bn | ≈ -5% | As above |
Twist Bioscience | FY2024 (Sep) | USD 313M | ≈ +28% | As above |
Recent Developments
Note on item 6: a KIND document excerpt surfaced in search listing 2024–2026 small public offerings and a 2024 change of largest shareholder to "포퓨쳐개발" appears to belong to a different issuer (its fiscal-period numbering and shareholder history do not match Celemics). These items have therefore been excluded* from Celemics' history and are noted here only for transparency.



